As macroeconomic forces and geopolitical dynamics continue to shape the M&A and investment climate globally, health and life sciences transactions continue to remain high priority sectors presenting both high growth and defensive asset strategies.
As the market has tightened, understanding the regulatory environment for investments has become even more important. Now, more than ever, investors want to pick sectors and companies well placed to take advantage of changes in regulation, pricing and government policies.
Please see full Publication below for more information.
